| Literature DB >> 23642018 |
Fotini Papachristou1, Ekaterini Chatzaki, Athanasios Petrou, Ioanna Kougioumtzi, Nikolaos Katsikogiannis, Alexandros Papalambros, Grigorios Tripsianis, Constantinos Simopoulos, Alexandra K Tsaroucha.
Abstract
BACKGROUND: Apigenin (4',5,7-trihydroxyflavone, AP), an active component of many medicinal Chinese herbs, exhibits anticancer properties in vitro and in vivo. This study aims to investigate the genotoxic, cytostatic, and cytotoxic effects of AP and time course changes in the levels of anti- and pro-apoptotic proteins involved in the DNA damage response in HepG2 cells.Entities:
Year: 2013 PMID: 23642018 PMCID: PMC3660279 DOI: 10.1186/1749-8546-8-9
Source DB: PubMed Journal: Chin Med ISSN: 1749-8546 Impact factor: 5.455
Figure 1The effect of apigenin on cell viability and induction of apoptosis. A. The cytotoxic and antiproliferative effect of apigenin in HepG2 cells. B. The apoptotic potential of apigenin (20 μΜ) after 24 h of treatment. The star (*) indicates statistical significance compared with control cultures.
The effect of apigenin on the frequency of chromosomal aberrations
| | ||||||||
|---|---|---|---|---|---|---|---|---|
| Untreated control | 300 | 55.8 ± 14.27 | 0.16 ± 0.03 | 0.51 ± 0.15 | 0.10 ± 0.07 | 0.20 ± 0.15 | 0.035 ± 0.03 | 0.010 ± 0.01 |
| Vehicle control | 300 | 60.5 ± 5.05 | 0.15 ± 0.09 | 0.63 ± 0.19 | 0.05 ± 0.03 | 0.32 ± 0.06 | 0.003 ± 0.01 | 0.003 ± 0.01 |
| AP (1 μM) | 303 | 56.2 ± 12.57 | 0.08 ± 0.01 | 0.49 ± 0.09 | 0.05 ± 0.03 | 0.27 ± 0.18 | 0.013 ± 0.02 | 0.003 ± 0.01 |
| ΑP (10 μΜ) | 300 | 68.2 ± 13.88 | 0.13 ± 0.07 | 0.63 ± 0.12 | 0.06 ± 0.02 | 0.33 ± 0.16 | 0.022 ± 0.03 | 0.000 ± 0.00 |
| AP (20 μΜ) | 300 | 66.0 ± 6.60 | 0.16 ± 0.06 | 0.56 ± 0.05 | 0.07 ± 0.03 | 0.41 ± 0.03 | 0.024 ± 0.02 | 0.010 ± 0.01 |
chtg: chromatid gap; chtb: chromatid break; f: fragment; chrg: chromosome gap; chrb: chromosome break; r: ring; d: dicentric.
The genotoxic, cytostatic, and cytotoxic potential of apigenin
| Untreated control | 0.17 ± 0.08 (0.04-0.42) | 2.64 ± 0.03 | 76.3 ± 9.50 |
| Vehicle control | 0.15 ± 0.08 (0.03-0.33) | 2.65 ± 0.06 | 87.3 ± 20.20 |
| AP (1 μM) | 0.15 ± 0.09 (0.04-0.42) | 2.61 ± 0.10 | 63.0 ± 19.52 |
| ΑP (10 μΜ) | 0.22 ± 0.14*,a (0.03-0.69) | 2.52 ± 0.13 | 57.0 ± 22.84 |
| AP (20 μΜ) | 0.26 ± 0.12*,b,c (0.07-0.64) | 2.09 ± 0.12*,d | 32.7 ± 7.96* |
| ΑP (50 μΜ) | ND | ND | 9.3 ± 7.57*,e |
*P ≤ 0.01 vs. vehicle control; aP < 0.01 vs. 1 μM; bP < 0.001 vs. 1 μM; cP < 0.05 vs. 10 μΜ; dP ≤ 0.001 vs. 1 and 10 μΜ; eP < 0.01 vs. 1, 10 and 20 μM. ND: values could not be determined.
The effect of apigenin on cell cycle kinetics
| Untreated control | 4.3 ± 1.15 | 39.0 ± 9.54 | 89.7 ± 20.55 |
| Vehicle control | 5.0 ± 2.65 | 42.0 ± 10.44 | 103.0 ± 9.17 |
| AP (1 μM) | 4.0 ± 2.65 | 50.0 ± 9.54 | 97.3 ± 14.05 |
| ΑP (10 μΜ) | 7.4 ± 3.65 | 57.2 ± 16.57 | 85.2 ± 17.34 |
| AP (20 μΜ) | 20.2 ± 5.40*,a,b | 89.4 ± 20.38*,c | 34.2 ± 16.45*,a,d |
*P ≤ 0.01 vs. vehicle control; aP < 0.01 vs. 1 μM; bP < 0.05 vs. 10 μΜ; cP < 0.05 vs. 1 and 10 μΜ; dP < 0.01 vs. 10 μΜ.
Figure 2The effect of apigenin on apoptosis-related proteins. A. The effect of apigenin (20 μΜ) treatment on sFas protein levels. Control cultures: 6 vs. 12 h, P = 0.005; 12 vs. 24 h, P = 0.001. Apigenin treatment: 3 vs. 6 h, P = 0.021; 6 vs. 12 h, P = 0.001; 12 vs. 24 h, P = 0.001; 24 vs. 48 h, P = 0.001. B. The effect of apigenin (20 μΜ) treatment on Bcl-2 protein levels. C. The effect of apigenin (20 μΜ) treatment on Bax protein levels. D. The effect of apigenin (20 μΜ) treatment on Bax/Bcl-2 ratio. According to linear regression analysis: Time intervals 1–12 h, R = 0.960, R2 = 0.921, P = 0.040; Time intervals 12–48 h, R = -0.957, R2 = 0.915, P = 0.188. The star (*) indicates statistical significance compared with the respective control cultures.